preclamol has been researched along with MPTP Neurotoxicity Syndrome in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown-Borg, HM; Ebadi, M; Muralikrishnan, D | 1 |
| Sonsalla, PK; Terleckyj, I | 1 |
2 other study(ies) available for preclamol and MPTP Neurotoxicity Syndrome
| Article | Year |
|---|---|
Dopamine agonist 3-PPP fails to protect against MPTP-induced toxicity.
Topics: Animals; Behavior, Animal; Cell Division; Cell Line, Tumor; Corpus Striatum; Dopamine; Dopamine Agonists; Humans; Mice; Mice, Inbred C57BL; Monoamine Oxidase; MPTP Poisoning; Neuroprotective Agents; Piperidines; Treatment Failure | 2004 |
The sigma receptor ligand (+/-)-BMY 14802 prevents methamphetamine-induced dopaminergic neurotoxicity via interactions at dopamine receptors.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Brain Diseases; Butaclamol; Carbazoles; Dizocilpine Maleate; Dopamine; Dopamine Agents; Drug Interactions; Drug Synergism; Guanidines; Ligands; Male; Methamphetamine; Mice; MPTP Poisoning; Neostriatum; Piperidines; Psychotropic Drugs; Pyrimidines; Receptors, Dopamine; Receptors, sigma; Stereoisomerism; Tyrosine 3-Monooxygenase | 1994 |